University of California San Francisco

Alan P. Venook - 144
Alan P. Venook, MD

Professor of Clinical Medicine,
Division of Hematology Oncology
Department of Medicine
Chairman, UCSF Committee on Human Research

Address

1450 Third Street, #376
San Francisco, CA 94158
United States

Email: [email protected]
Phone: 415-353-2745
Fax: 415-353-7779

ORCID: 0000-0001-9749-6548

Biography

Dr. Venook is a Medical Oncologist with expertise in Gastrointestinal cancers.  He leads that program in the UCSF 
Helen Diller Family Comprehensive Cancer Center. The program boasts a robust clinical trials portfolio primarily for patients in need of new options.

Education

Institution Degree Dept or School End Date
University of California, San Francisco M.D. Medicine 1980
University of California, San Francisco Residency School of Medicine

Board Certifications

American Board of Internal Medicine
American Board of Internal Medicine: Medical Oncology - Subspecialty
American Board of Internal Medicine: Hematology  - Subspecialty

Awards & Honors

Award Conferred By Date
Giant of Cancer Care in GI Oncology Giants of Cancer Care 2019
Heroes of Hope Award Colon Cancer Alliance 2017
NCCN Board of Producers Award National Comprehensive Cancer Network 2013
Service Excellence Award Healthnetwork Foundation 2011
Director's Service Award National Cancer Institute 2010

Clinical Expertise

Anal Cancer
Colon Cancer
Esophageal Cancer
Hepatocellular Carcinoma (Liver Cancer)
Liver Metastases
Lynch Syndrome
Pancreatic Cancer
Rectal Cancer
Stomach Cancer

Clinical Trials

  1. Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer (NCT00265850)
    Related Conditions: Colorectal Cancer, Colorectal Tumor| Start Date: | End Date:
  2. Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma (NCT01008917)
    Related Conditions: Hepatocellular Cancer, Liver Cancer, Carcinoma| Start Date: | End Date:
  3. FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum (NCT00077233)
    Related Conditions: Colorectal Cancer| Start Date: | End Date:
  4. Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis (NCT00003368)
    Related Conditions: Lymphoma, Small Intestine Cancer, Solid Tumor| Start Date: | End Date:
  5. Celecoxib and Erlotinib in Treating Patients With Liver Cancer (NCT00293436)
    Related Conditions: Liver Cancer| Start Date:

Program Affiliations

UCSF Helen Diller Family Comprehensive Cancer Center
GI Oncology Program
The Liver Center at UCSF

Grants and Funding

  • Cancer Center Support Grant | NIH | 1999-08-05 - 2023-05-31 | Role: Co-Investigator
  • General Clinical Research Center | NIH | 1974-12-01 - 2009-03-31 | Role: Co-Investigator
  • CANCER AND LEUKEMIA GROUP B | NIH | 1993-07-28 - 2003-03-31 | Role: Principal Investigator

Research Interests

Anal Cancer
Colon Cancer
Hepatocellular Carcinoma (Liver Cancer)
Liver Metastases
Rectal Cancer

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 339
  1. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
    Benson AB, Venook AP, Adam M, Chang G, Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Haste P, Hecht JR, Hoffe S, Hunt S, Hussan H, Johung KL, Joseph N, Kirilcuk N, Krishnamurthi S, Malla M, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Shogan B, Skibber JM, Sofocleous CT, Tavakkoli A, Willett CG, Wu C, Gurski LA, Snedeker J, Jones F| | PubMed
  2. Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance).
    Quintanilha JCF, Sibley AB, Liu Y, Niedzwiecki D, Halabi S, Rogers L, O'Neil B, Kindler H, Kelly W, Venook A, McLeod HL, Ratain MJ, Nixon AB, Innocenti F, Owzar K| | PubMed
  3. DPYD Pharmacogenetics: To Opt-in or to Opt-out.
    Tamraz B, Venook AP| | PubMed
  4. q-Diffusion leverages the full dimensionality of gene coexpression in single-cell transcriptomics.
    Marmarelis MG, Littman R, Battaglin F, Niedzwiecki D, Venook A, Ambite JL, Galstyan A, Lenz HJ, Ver Steeg G| | PubMed
  5. Gene expression biomarkers differentiate overall survival of colorectal cancer upon targeted therapies.
    Yazdani A, Yazdani A, Mendez-Giraldez R, Pillonetto G, Samiei E, Hadi R, Lenz HJ, Venook A, Samiei A, Nixon A, Lucci J, Kopetz S, Bertagnolli M, Perou C, Innocenti F| | PubMed
  6. HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405.
    Battaglin F, Ou FS, Qu X, Hochster HS, Niedzwiecki D, Goldberg RM, Mayer RJ, Ashouri K, Zemla TJ, Blanke CD, Venook AP, Kabbarah O, Lenz HJ, Innocenti F| | PubMed
  7. CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma.
    Abou-Alfa GK, Geyer SM, Nixon AB, Innocenti F, Shi Q, Kumthekar P, Jacobson S, El Dika I, Yaqubie A, Lopez J, Huang B, Tang YW, Wen Y, Schwartz LH, El-Khoueiry AB, Knox JJ, Rajdev L, Bertagnolli MM, Meyerhardt JA, O'Reilly EM, Venook AP| | PubMed
  8. Evaluation of Culture Conducive to Academic Success by Gender at a Comprehensive Cancer Center.
    Keenan BP, Sibley A, Zhang L, Westring AF, Velazquez AI, Bank EM, Bergsland EK, Boreta L, Conroy P, Daras M, Hermiston M, Hsu G, Paris PL, Piawah S, Sinha S, Sosa JA, Tsang M, Venook AP, Wong M, Yom SS, Van Loon K| | PubMed
  9. Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer.
    Arai H, Yang Y, Baca Y, Millstein J, Denda T, Ou FS, Innocenti F, Takeda H, Kubota Y, Doi A, Horie Y, Umemoto K, Izawa N, Wang J, Battaglin F, Jayachandran P, Algaze S, Soni S, Zhang W, Goldberg RM, Hall MJ, Scott AJ, Hwang JJ, Lou E, Weinberg BA, Marshall J, Goel S, Xiu J, Michael Korn W, Venook AP, Sunakawa Y, Lenz HJ| | PubMed
  10. CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value.
    Battaglin F, Baca Y, Millstein J, Yang Y, Xiu J, Arai H, Wang J, Ou FS, Innocenti F, Mumenthaler SM, Jayachandran P, Kawanishi N, Lenz A, Soni S, Algaze S, Zhang W, Khoukaz T, Roussos Torres E, Seeber A, Abraham JP, Lou E, Philip PA, Weinberg BA, Shields AF, Goldberg RM, Marshall JL, Venook AP, Korn WM, Lenz HJ| | PubMed
339
View all 339 Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 339
  1. Associations between early tumor shrinkage/depth of response and survivals from the ARCAD database.
    Bando H, Takeda Y, Misumi T, Nishikawa T, Wakabayashi M, Yamazaki K, Oki E, Douillard JY, Punt CJA, Koopman M, Van Cutsem E, Bokemeyer C, Venook AP, Lenz HJ, Maehara Y, Andre T, Shi Q, de Gramont A, Yoshino T| | PubMed
  2. Expansion of a bacterial operon during cancer treatment ameliorates fluoropyrimidine toxicity.
    Trepka KR, Kidder WA, Kyaw TS, Halsey T, Olson CA, Ortega EF, Noecker C, Upadhyay V, Stanfield D, Steiding P, Guthrie BGH, Spanogiannopoulos P, Dumlao D, Turnbaugh JA, Stachler MD, Van Blarigan EL, Venook AP, Atreya CE, Turnbaugh PJ| | PubMed
  3. Gene signatures derived from transcriptomic-causal networks stratify colorectal cancer patients for effective targeted therapy.
    Yazdani A, Lenz HJ, Pillonetto G, Mendez-Giraldez R, Yazdani A, Sanoff H, Hadi R, Samiei E, Venook AP, Ratain MJ, Rashid N, Vincent BG, Qu X, Wen Y, Kosorok M, Symmans WF, Shen JPYC, Lee MS, Kopetz S, Nixon AB, Bertagnolli MM, Perou CM, Innocenti F| | PubMed
  4. Plant-based diet and survival among patients with metastatic colorectal cancer.
    Cheng E, Ou FS, Gatten C, Ma C, Venook AP, Lenz HJ, O'Reilly EM, Campbell PT, Kuang C, Caan BJ, Blanke CD, Ng K, Meyerhardt JA| | PubMed
  5. Reply to: "Give Patients the Choice to Test for DPD Deficiency Before Fluoropyrimidine Chemotherapy," "Large-Scale DPD Testing Should Be More Than an Option," and "A Big Problem With a Feasible Solution, Not a Small Problem With a Complex Solution".
    Tamraz B, Venook AP| | PubMed
  6. Changes in alpha-fetoprotein across the systemic therapy continuum in advanced hepatocellular carcinoma-a real-world, multicenter study.
    Li M, Hannan LM, Goyal L, Bocobo AG, Parks AL, Bauer K, Baiev I, Dinicola C, Gordan JD, Venook AP, Harris WP, Bracci P, Kelley RK| | PubMed
  7. Expansion of a bacterial operon during cancer treatment ameliorates drug toxicity.
    Trepka KR, Kidder WA, Kyaw TS, Halsey T, Olson CA, Ortega EF, Noecker C, Upadhyay V, Stanfield D, Steiding P, Guthrie BGH, Spanogiannopoulos P, Dumlao D, Turnbaugh JA, Stachler MD, Van Blarigan EL, Venook AP, Atreya CE, Turnbaugh PJ| | PubMed
  8. Association between gastrointestinal symptoms and specialty care utilization among colon cancer survivors: a cohort study.
    Edwards AL, Trang K, Tolstykh IV, Van Blarigan EL, Van Loon K, Laffan A, Stanfield D, Steiding P, Neuhaus J, Atreya CE, Piawah S, Venook AP, Varma MG| | PubMed
  9. NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024.
    Benson AB, Venook AP, Adam M, Chang G, Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Haste P, Hecht JR, Hoffe S, Hunt S, Hussan H, Johung KL, Joseph N, Kirilcuk N, Krishnamurthi S, Malla M, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Shogan B, Skibber JM, Sofocleous CT, Tavakkoli A, Willett CG, Wu C, Jones F, Gurski L| | PubMed
  10. Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.
    Cohen R, Raeisi M, Chibaudel B, Shi Q, Yoshino T, Zalcberg JR, Adams R, Cremolini C, Van Cutsem E, Heinemann V, Tabernero J, Punt CJA, Arnold D, Hurwitz HI, Douillard JY, Venook AP, Saltz LB, Maughan TS, Kabbinavar F, Bokemeyer C, Grothey A, Mayer RJ, Kaplan R, Tebbutt NC, Randolph Hecht J, Giantonio BJ, Díaz-Rubio E, Sobrero AF, Peeters M, Koopman M, Goldberg RM, Andre T, de Gramont A| | PubMed
  11. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
    Benson AB, Venook AP, Adam M, Chang G, Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Haste P, Hecht JR, Hoffe S, Hunt S, Hussan H, Johung KL, Joseph N, Kirilcuk N, Krishnamurthi S, Malla M, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Shogan B, Skibber JM, Sofocleous CT, Tavakkoli A, Willett CG, Wu C, Gurski LA, Snedeker J, Jones F| | PubMed
  12. Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance).
    Quintanilha JCF, Sibley AB, Liu Y, Niedzwiecki D, Halabi S, Rogers L, O'Neil B, Kindler H, Kelly W, Venook A, McLeod HL, Ratain MJ, Nixon AB, Innocenti F, Owzar K| | PubMed
  13. DPYD Pharmacogenetics: To Opt-in or to Opt-out.
    Tamraz B, Venook AP| | PubMed
  14. q-Diffusion leverages the full dimensionality of gene coexpression in single-cell transcriptomics.
    Marmarelis MG, Littman R, Battaglin F, Niedzwiecki D, Venook A, Ambite JL, Galstyan A, Lenz HJ, Ver Steeg G| | PubMed
  15. Gene expression biomarkers differentiate overall survival of colorectal cancer upon targeted therapies.
    Yazdani A, Yazdani A, Mendez-Giraldez R, Pillonetto G, Samiei E, Hadi R, Lenz HJ, Venook A, Samiei A, Nixon A, Lucci J, Kopetz S, Bertagnolli M, Perou C, Innocenti F| | PubMed
  16. HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405.
    Battaglin F, Ou FS, Qu X, Hochster HS, Niedzwiecki D, Goldberg RM, Mayer RJ, Ashouri K, Zemla TJ, Blanke CD, Venook AP, Kabbarah O, Lenz HJ, Innocenti F| | PubMed
  17. CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma.
    Abou-Alfa GK, Geyer SM, Nixon AB, Innocenti F, Shi Q, Kumthekar P, Jacobson S, El Dika I, Yaqubie A, Lopez J, Huang B, Tang YW, Wen Y, Schwartz LH, El-Khoueiry AB, Knox JJ, Rajdev L, Bertagnolli MM, Meyerhardt JA, O'Reilly EM, Venook AP| | PubMed
  18. Evaluation of Culture Conducive to Academic Success by Gender at a Comprehensive Cancer Center.
    Keenan BP, Sibley A, Zhang L, Westring AF, Velazquez AI, Bank EM, Bergsland EK, Boreta L, Conroy P, Daras M, Hermiston M, Hsu G, Paris PL, Piawah S, Sinha S, Sosa JA, Tsang M, Venook AP, Wong M, Yom SS, Van Loon K| | PubMed
  19. Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer.
    Arai H, Yang Y, Baca Y, Millstein J, Denda T, Ou FS, Innocenti F, Takeda H, Kubota Y, Doi A, Horie Y, Umemoto K, Izawa N, Wang J, Battaglin F, Jayachandran P, Algaze S, Soni S, Zhang W, Goldberg RM, Hall MJ, Scott AJ, Hwang JJ, Lou E, Weinberg BA, Marshall J, Goel S, Xiu J, Michael Korn W, Venook AP, Sunakawa Y, Lenz HJ| | PubMed
  20. CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value.
    Battaglin F, Baca Y, Millstein J, Yang Y, Xiu J, Arai H, Wang J, Ou FS, Innocenti F, Mumenthaler SM, Jayachandran P, Kawanishi N, Lenz A, Soni S, Algaze S, Zhang W, Khoukaz T, Roussos Torres E, Seeber A, Abraham JP, Lou E, Philip PA, Weinberg BA, Shields AF, Goldberg RM, Marshall JL, Venook AP, Korn WM, Lenz HJ| | PubMed
  21. Gene signatures derived from transcriptomic-causal networks stratified colorectal cancer patients for effective targeted therapy.
    Yazdani A, Lenz HJ, Pillonetto G, Mendez-Giraldez R, Yazdani A, Sanof H, Hadi R, Samiei E, Venook AP, Ratain MJ, Rashid N, Vincent BG, Qu X, Wen Y, Kosorok M, Symmans WF, Shen JPYC, Lee MS, Kopetz S, Nixon AB, Bertagnolli MM, Perou CM, Innocenti F| | PubMed
  22. Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance).
    Quintanilha JCF, Sibley AB, Liu Y, Niedzwiecki D, Halabi S, Rogers L, O'Neil B, Kindler H, Kelly W, Venook A, McLeod HL, Ratain MJ, Nixon AB, Innocenti F, Owzar K| | PubMed
  23. DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations.
    Innocenti F, Mu W, Qu X, Ou FS, Kabbarah O, Blanke CD, Venook AP, Lenz HJ, Rashid NU| | PubMed
  24. Associations between the Gut Microbiota, Race, and Ethnicity of Patients with Colorectal Cancer: A Pilot and Feasibility Study.
    Piawah S, Kyaw TS, Trepka K, Stewart AL, Mora RV, Stanfield D, Levine K, Van Blarigan EL, Venook A, Turnbaugh PJ, Nguyen T, Atreya CE| | PubMed
  25. Physical activity in recurrent colon cancer: Cancer and Leukemia Group B/SWOG 80702 (Alliance).
    Brown JC, Ma C, Shi Q, Zemla T, Couture F, Kuebler P, Kumar P, Tan B, Krishnamurthi S, Chang V, Goldberg RM, Venook AP, Blanke CD, O'Reilly EM, Shields AF, Meyerhardt JA| | PubMed
  26. Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database.
    Ou FS, Ahn DH, Dixon JG, Grothey A, Lou Y, Kasi PM, Hubbard JM, Van Cutsem E, Saltz LB, Schmoll HJ, Goldberg RM, Venook AP, Hoff P, Douillard JY, Hecht JR, Hurwitz H, Punt CJA, Koopman M, Bokemeyer C, Fuchs CS, Diaz-Rubio E, Tebbutt NC, Cremolini C, Kabbinavar FF, Bekaii-Saab T, Chibaudel B, Yoshino T, Zalcberg J, Adams RA, de Gramont A, Shi Q| | PubMed
  27. Variety of Fruit and Vegetables and Alcohol Intake are Associated with Gut Microbial Species and Gene Abundance in Colorectal Cancer Survivors.
    Kyaw TS, Upadhyay V, Tolstykh I, Van Loon K, Laffan A, Stanfield D, Gempis D, Kenfield SA, Chan JM, Piawah S, Atreya CE, Ng K, Venook A, Kidder W, Turnbaugh PJ, Van Blarigan EL| | PubMed
  28. Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance).
    Wang QL, Ma C, Yuan C, Shi Q, Wolpin BM, Zhang Y, Fuchs CS, Meyer J, Zemla T, Cheng E, Kumthekar P, Guthrie KA, Couture F, Kuebler P, Kumar P, Tan B, Krishnamurthi S, Goldberg RM, Venook A, Blanke C, Shields AF, O'Reilly EM, Meyerhardt JA, Ng K| | PubMed
  29. Barriers and confidence among colorectal and prostate cancer survivors participating in two behavioral intervention studies.
    Liu VN, Zuniga KB, Paciorek A, Zhang L, Chan JM, Carroll PR, Van Loon K, Laffan A, Venook A, Van Blarigan EL, Kenfield SA| | PubMed
  30. Flashback Foreword: IFL/FOLFOX/IROX in Advanced Colorectal Cancer and FOLFIRI and FOLFOX6 in Colorectal Cancer.
    Venook AP| | PubMed
  31. NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023.
    Benson AB, D'Angelica MI, Abrams T, Abbott DE, Ahmed A, Anaya DA, Anders R, Are C, Bachini M, Binder D, Borad M, Bowlus C, Brown D, Burgoyne A, Castellanos J, Chahal P, Cloyd J, Covey AM, Glazer ES, Hawkins WG, Iyer R, Jacob R, Jennings L, Kelley RK, Kim R, Levine M, Palta M, Park JO, Raman S, Reddy S, Ronnekleiv-Kelly S, Sahai V, Singh G, Stein S, Turk A, Vauthey JN, Venook AP, Yopp A, McMillian N, Schonfeld R, Hochstetler C| | PubMed
  32. Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048).
    Basch E, Dueck AC, Mitchell SA, Mamon H, Weiser M, Saltz L, Gollub M, Rogak L, Ginos B, Mazza GL, Colgrove B, Chang G, Minasian L, Denicoff A, Thanarajasingam G, Musher B, George T, Venook A, Farma J, O'Reilly E, Meyerhardt JA, Shi Q, Schrag D| | PubMed
  33. Preoperative Treatment of Locally Advanced Rectal Cancer.
    Schrag D, Shi Q, Weiser MR, Gollub MJ, Saltz LB, Musher BL, Goldberg J, Al Baghdadi T, Goodman KA, McWilliams RR, Farma JM, George TJ, Kennecke HF, Shergill A, Montemurro M, Nelson GD, Colgrove B, Gordon V, Venook AP, O'Reilly EM, Meyerhardt JA, Dueck AC, Basch E, Chang GJ, Mamon HJ| | PubMed
  34. Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
    Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Hecht JR, Hoffe S, Hubbard J, Hunt S, Hussan H, Jeck W, Johung KL, Joseph N, Kirilcuk N, Krishnamurthi S, Maratt J, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stotsky-Himelfarb E, Tavakkoli A, Willett CG, Williams G, Algieri F, Gurski L, Stehman K| | PubMed
  35. Neoadjuvant Immunotherapy for Colorectal Cancer: Too Good to Be True?
    Venook AP| | PubMed
  36. Sexual function remains persistently low in women after treatment for colorectal cancer and anal squamous cell carcinoma.
    Savoie MB, Paciorek A, Van Loon K, Anwar M, Atreya CE, Johnson PC, Kenfield SA, Laffan A, Levin AO, Smith JF, Stanfield D, Venook A, Zhang L, Van Blarigan EL, Rowen T| | PubMed
  37. Defining incidence and complications of fibrolamellar liver cancer through tiered computational analysis of clinical data.
    Zack T, Losert KP, Maisel SM, Wild J, Yaqubie A, Herman M, Knox JJ, Mayer RJ, Venook AP, Butte A, O'Neill AF, Abou-Alfa GK, Gordan JD| | PubMed
  38. Quality of life among colorectal cancer survivors participating in a pilot randomized controlled trial of a web-based dietary intervention with text messages.
    Wang L, Langlais C, Kenfield SA, Van Loon K, Laffan A, Atreya CE, Chan JM, Zhang L, Allen IE, Miaskowski C, Fukuoka Y, Meyerhardt JA, Venook AP, Van Blarigan EL| | PubMed
  39. Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with 90Y resin microspheres for chemo-refractory colorectal liver metastases.
    Fidelman N, Atreya CE, Griffith M, Milloy MA, Carnevale J, Cinar P, Venook AP, Van Loon K| | PubMed
  40. Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702.
    Lee S, Ma C, Shi Q, Kumar P, Couture F, Kuebler P, Krishnamurthi S, Lewis D, Tan B, Goldberg RM, Venook A, Blanke C, O'Reilly EM, Shields AF, Meyerhardt JA| | PubMed
  41. Association between adherence to the American Cancer Society Nutrition and Physical Activity Guidelines and stool frequency among colon cancer survivors: a cohort study.
    Greenberg AL, Tolstykh IV, Van Loon K, Laffan A, Stanfield D, Steiding P, Kenfield SA, Chan JM, Atreya CE, Piawah S, Kidder W, Venook AP, Van Blarigan EL, Varma MG| | PubMed
  42. Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (E1292).
    Kemeny MM, Zhao F, Forastiere AA, Catalano P, Hamilton SR, Miedema BW, Dawson NA, Weiner LM, Smith BD, Mason BA, Graziano SL, Gilman PB, Venook AP, Pinto HA, Whitehead RP, O'Dwyer PJ, Benson AB| | PubMed
  43. Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
    Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Gunn A, Hecht JR, Hoffe S, Hubbard J, Hunt S, Jeck W, Johung KL, Kirilcuk N, Krishnamurthi S, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stotsky-Himelfarb E, Tavakkoli A, Willett CG, Gregory K, Gurski L| | PubMed
  44. Host and gut bacteria share metabolic pathways for anti-cancer drug metabolism.
    Spanogiannopoulos P, Kyaw TS, Guthrie BGH, Bradley PH, Lee JV, Melamed J, Malig YNA, Lam KN, Gempis D, Sandy M, Kidder W, Van Blarigan EL, Atreya CE, Venook A, Gerona RR, Goga A, Pollard KS, Turnbaugh PJ| | PubMed
  45. ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer.
    Johnson RM, Qu X, Lin CF, Huw LY, Venkatanarayan A, Sokol E, Ou FS, Ihuegbu N, Zill OA, Kabbarah O, Wang L, Bourgon R, de Sousa E Melo F, Bolen C, Daemen A, Venook AP, Innocenti F, Lenz HJ, Bais C| | PubMed
  46. Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance).
    Raghav K, Ou FS, Venook AP, Innocenti F, Sun R, Lenz HJ, Kopetz S| | PubMed
  47. Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial.
    Katz MHG, Shi Q, Meyers J, Herman JM, Chuong M, Wolpin BM, Ahmad S, Marsh R, Schwartz L, Behr S, Frankel WL, Collisson E, Leenstra J, Williams TM, Vaccaro G, Venook A, Meyerhardt JA, O'Reilly EM| | PubMed
  48. Dietary fat in relation to all-cause mortality and cancer progression and death among people with metastatic colorectal cancer: Data from CALGB 80405 (Alliance)/SWOG 80405.
    Van Blarigan EL, Ma C, Ou FS, Bainter TM, Venook AP, Ng K, Niedzwiecki D, Giovannucci E, Lenz HJ, Polite BN, Hochster HS, Goldberg RM, Mayer RJ, Blanke CD, O'Reilly EM, Ciombor KK, Meyerhardt JA| | PubMed
  49. Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance).
    Nixon AB, Sibley AB, Liu Y, Hatch AJ, Jiang C, Mulkey F, Starr MD, Brady JC, Niedzwiecki D, Venook AP, Baez-Diaz L, Lenz HJ, O'Neil BH, Innocenti F, Meyerhardt JA, O'Reilly EM, Owzar K, Hurwitz HI| | PubMed
  50. Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance).
    Kulke MH, Ou FS, Niedzwiecki D, Huebner L, Kunz P, Kennecke HF, Wolin EM, Chan JA, O'Reilly EM, Meyerhardt JA, Venook A| | PubMed
  51. Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab.
    Innocenti F, Yazdani A, Rashid N, Qu X, Ou FS, Van Buren S, Bertagnolli MM, Kabbarah O, Blanke CD, Venook AP, Lenz HJ, Vincent BG| | PubMed
  52. Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405.
    Lipsyc-Sharf M, Zhang S, Ou FS, Ma C, McCleary NJ, Niedzwiecki D, Chang IW, Lenz HJ, Blanke CD, Piawah S, Van Loon K, Bainter TM, Venook AP, Mayer RJ, Fuchs CS, Innocenti F, Nixon AB, Goldberg R, O'Reilly EM, Meyerhardt JA, Ng K| | PubMed
  53. Colorectal Cancer Surveillance With Circulating Tumor DNA Assay.
    Venook AP| | PubMed
  54. Quality of life of colorectal cancer survivors participating in a pilot randomized controlled trial of physical activity trackers and daily text messages.
    Chan H, Van Loon K, Kenfield SA, Chan JM, Mitchell E, Zhang L, Paciorek A, Joseph G, Laffan A, Atreya C, Fukuoka Y, Miaskowski C, Meyerhardt JA, Venook AP, Van Blarigan EL| | PubMed
  55. Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer.
    Van Blarigan EL, Ou FS, Bainter TM, Fuchs CS, Niedzwiecki D, Zhang S, Saltz LB, Mayer RJ, Hantel A, Benson AB, Atienza D, Messino M, Kindler HL, Venook AP, Ogino S, Sanoff HK, Giovannucci EL, Ng K, Meyerhardt JA| | PubMed
  56. Patient-specific meta-analysis of 12-gene colon cancer recurrence score validation studies for recurrence risk assessment after surgery with or without 5FU and oxaliplatin.
    Yothers G, Venook AP, Oki E, Niedzwiecki D, Lin Y, Crager MR, Chao C, Baehner FL, Wolmark N, Yoshino T| | PubMed
  57. Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis.
    McCleary NJ, Zhang S, Ma C, Ou FS, Bainter TM, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, O'Neil BH, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Ng K, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA| | PubMed
  58. Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years.
    Papamichael D, Lopes GS, Olswold CL, Douillard JY, Adams RA, Maughan TS, Van Cutsem E, Venook AP, Lenz HJ, Heinemann V, Kaplan R, Bokemeyer C, Chibaudel B, Grothey A, Yoshino T, Zalcberg J, De Gramont A, Shi Q| | PubMed
  59. Feasibility and Acceptability of a Physical Activity Tracker and Text Messages to Promote Physical Activity During Chemotherapy for Colorectal Cancer: Pilot Randomized Controlled Trial (Smart Pace II).
    Van Blarigan EL, Dhruva A, Atreya CE, Kenfield SA, Chan JM, Milloy A, Kim I, Steiding P, Laffan A, Zhang L, Piawah S, Fukuoka Y, Miaskowski C, Hecht FM, Kim MO, Venook AP, Van Loon K| | PubMed
  60. Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer.
    Yin J, Cohen R, Jin Z, Liu H, Pederson L, Adams R, Grothey A, Maughan TS, Venook A, Van Cutsem E, Punt C, Koopman M, Falcone A, Tebbutt NC, Seymour MT, Bokemeyer C, Rubio ED, Kaplan R, Heinemann V, Chibaudel B, Yoshino T, Zalcberg J, Andre T, De Gramont A, Shi Q, Lenz HJ| | PubMed
  61. Being Present 2.0: Online Mindfulness-Based Program for Metastatic Gastrointestinal Cancer Patients and Caregivers.
    Dragomanovich HM, Dhruva A, Ekman E, Schoenbeck KL, Kubo A, Van Blarigan EL, Borno HT, Esquivel M, Chee B, Campanella M, Philip EJ, Rettger JP, Rosenthal B, Van Loon K, Venook AP, Boscardin C, Moran P, Hecht FM, Atreya CE| | PubMed
  62. Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer.
    Arai H, Elliott A, Millstein J, Xiu J, Ou FS, Innocenti F, Wang J, Battaglin F, Jayachandran P, Kawanishi N, Soni S, Zhang W, Sohal D, Goldberg RM, Hall MJ, Scott AJ, Khushman M, Hwang JJ, Lou E, Weinberg BA, Lockhart AC, Shields AF, Abraham JP, Magee D, Stafford P, Zhang J, Venook AP, Korn WM, Lenz HJ| | PubMed
  63. Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens.
    Quintanilha JCF, Wang J, Sibley AB, Xu W, Espin-Garcia O, Jiang C, Etheridge AS, Ratain MJ, Lenz HJ, Bertagnolli M, Kindler HL, Dickler MN, Venook A, Liu G, Owzar K, Lin D, Innocenti F| | PubMed
  64. BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database.
    Cohen R, Liu H, Fiskum J, Adams R, Chibaudel B, Maughan TS, Van Cutsem E, Venook A, Douillard JY, Heinemann V, Ja Punt C, Falcone A, Bokemeyer C, Kaplan R, Lenz HJ, Koopman M, Yoshino T, Zalcberg J, Grothey A, de Gramont A, Shi Q, André T| | PubMed
  65. Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma with Tumor Mutation Profiling.
    Kelley RK, Joseph NM, Nimeiri HS, Hwang J, Kulik LM, Ngo Z, Behr SC, Onodera C, Zhang K, Bocobo AG, Benson AB, Venook AP, Gordan JD| | PubMed
  66. Racial differences in survival and response to therapy in patients with metastatic colorectal cancer: A secondary analysis of CALGB/SWOG 80405 (Alliance A151931).
    Snyder RA, He J, Le-Rademacher J, Ou FS, Dodge AB, Zemla TJ, Paskett ED, Chang GJ, Innocenti F, Blanke C, Lenz HJ, Polite BN, Venook AP| | PubMed
  67. Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis.
    Yin J, Dawood S, Cohen R, Meyers J, Zalcberg J, Yoshino T, Seymour M, Maughan T, Saltz L, Van Cutsem E, Venook A, Schmoll HJ, Goldberg R, Hoff P, Hecht JR, Hurwitz H, Punt C, Diaz Rubio E, Koopman M, Cremolini C, Heinemann V, Tournigard C, Bokemeyer C, Fuchs C, Tebbutt N, Souglakos J, Doulliard JY, Kabbinavar F, Chibaudel B, de Gramont A, Shi Q, Grothey A, Adams R| | PubMed
  68. Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial.
    Goodman KA, Ou FS, Hall NC, Bekaii-Saab T, Fruth B, Twohy E, Meyers MO, Boffa DJ, Mitchell K, Frankel WL, Niedzwiecki D, Noonan A, Janjigian YY, Thurmes PJ, Venook AP, Meyerhardt JA, O'Reilly EM, Ilson DH| | PubMed
  69. Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
    Benson AB, D'Angelica MI, Abbott DE, Anaya DA, Anders R, Are C, Bachini M, Borad M, Brown D, Burgoyne A, Chahal P, Chang DT, Cloyd J, Covey AM, Glazer ES, Goyal L, Hawkins WG, Iyer R, Jacob R, Kelley RK, Kim R, Levine M, Palta M, Park JO, Raman S, Reddy S, Sahai V, Schefter T, Singh G, Stein S, Vauthey JN, Venook AP, Yopp A, McMillian NR, Hochstetler C, Darlow SD| | PubMed
  70. Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance).
    Lee S, Zhang S, Ma C, Ou FS, Wolfe EG, Ogino S, Niedzwiecki D, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Gross CP, Irwin ML, Meyerhardt JA, Fuchs CS| | PubMed
  71. Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.
    Meyerhardt JA, Shi Q, Fuchs CS, Meyer J, Niedzwiecki D, Zemla T, Kumthekar P, Guthrie KA, Couture F, Kuebler P, Bendell JC, Kumar P, Lewis D, Tan B, Bertagnolli M, Grothey A, Hochster HS, Goldberg RM, Venook A, Blanke C, O'Reilly EM, Shields AF| | PubMed
  72. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
    Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Farkas L, Garrido-Laguna I, Grem JL, Gunn A, Hecht JR, Hoffe S, Hubbard J, Hunt S, Johung KL, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Gurski LA| | PubMed
  73. Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer.
    Abraham JP, Magee D, Cremolini C, Antoniotti C, Halbert DD, Xiu J, Stafford P, Berry DA, Oberley MJ, Shields AF, Marshall JL, Salem ME, Falcone A, Grothey A, Hall MJ, Venook AP, Lenz HJ, Helmstetter A, Korn WM, Spetzler DB| | PubMed
  74. Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer.
    Mackintosh C, Yuan C, Ou FS, Zhang S, Niedzwiecki D, Chang IW, O'Neil BH, Mullen BC, Lenz HJ, Blanke CD, Venook AP, Mayer RJ, Fuchs CS, Innocenti F, Nixon AB, Goldberg RM, O'Reilly EM, Meyerhardt JA, Ng K| | PubMed
  75. Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance).
    Innocenti F, Sibley AB, Patil SA, Etheridge AS, Jiang C, Ou FS, Howell SD, Plummer SJ, Casey G, Bertagnolli MM, McLeod HL, Auman JT, Blanke CD, Furukawa Y, Venook AP, Kubo M, Lenz HJ, Parker JS, Ratain MJ, Owzar K| | PubMed
  76. IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405.
    Guercio BJ, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Pollak MN, Nixon AB, Mullen BC, O'Neil BH, Shaw JE, Polite BN, Benson AB, Atkins JN, Goldberg RM, Brown JC, O'Reilly EM, Mayer RJ, Blanke CD, Fuchs CS, Meyerhardt JA| | PubMed
  77. Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer.
    Ko AH, Jordan AC, Tooker E, Lacey SF, Chang RB, Li Y, Venook AP, Tempero M, Damon L, Fong L, O'Hara MH, Levine BL, Melenhorst JJ, Plesa G, June CH, Beatty GL| | PubMed
  78. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper.
    Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, Dwyer A, Diehn M, Eng C, George TJ, Gollub MJ, Goodwin RA, Hamilton SR, Hechtman JF, Hochster H, Hong TS, Innocenti F, Iqbal A, Jacobs SA, Kennecke HF, Lee JJ, Lieu CH, Lenz HJ, Lindwasser OW, Montagut C, Odisio B, Ou FS, Porter L, Raghav K, Schrag D, Scott AJ, Shi Q, Strickler JH, Venook A, Yaeger R, Yothers G, You YN, Zell JA, Kopetz S| | PubMed
  79. NCCN Guidelines Insights: Rectal Cancer, Version 6.2020.
    Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Gunn A, Hoffe S, Hubbard J, Hunt S, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Johnson-Chilla A, Gurski LA| | PubMed
  80. Factors Impacting Differential Outcomes in the Definitive Radiation Treatment of Anal Cancer Between HIV-Positive and HIV-Negative Patients.
    Susko M, Wang CJ, Lazar AA, Kim S, Laffan A, Feng M, Ko A, Venook AP, Atreya CE, Van Loon K, Anwar M| | PubMed
  81. A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma.
    El Dika I, Mayer RJ, Venook AP, Capanu M, LaQuaglia MP, Kobos R, O'Neill AF, Chou JF, Ly M, Ang C, O'Reilly EM, Gordan JD, Abou-Alfa GK| | PubMed
  82. Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405.
    Guercio BJ, Zhang S, Venook AP, Ou FS, Niedzwiecki D, Lenz HJ, Innocenti F, Mullen BC, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Brown JC, O'Reilly EM, Mayer RJ, Blanke CD, Fuchs CS, Meyerhardt JA| | PubMed
  83. Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma.
    Abou-Alfa GK, Mayer R, Venook AP, O'Neill AF, Beg MS, LaQuaglia M, Kingham PT, Kobos R, Basturk O, Brennan C, Yopp A, Harding JJ, Leong S, Crown J, Hoti E, Leonard G, Ly M, Bradley M, Valentino E, Markowitz D, Zukiwski A, Ren K, Gordan JD| | PubMed
  84. Clinicopathologic Characteristics and Impact of Oophorectomy for Ovarian Metastases from Colorectal Cancer.
    Ursem C, Zhou M, Paciorek A, Atreya CE, Ko AH, Venook A, Zhang L, Van Loon K| | PubMed
  85. Feasibility and Acceptability of a Web-Based Dietary Intervention with Text Messages for Colorectal Cancer: A Randomized Pilot Trial.
    Van Blarigan EL, Kenfield SA, Chan JM, Van Loon K, Paciorek A, Zhang L, Chan H, Savoie MB, Bocobo AG, Liu VN, Wong LX, Laffan A, Atreya CE, Miaskowski C, Fukuoka Y, Meyerhardt JA, Venook AP| | PubMed
  86. Heated Intraperitoneal Chemotherapy for Colorectal Carcinomatosis: Emerging Evidence.
    Snyder RA, Fournier K, Royal R, Venook AP, Chang GJ| | PubMed
  87. Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation.
    Savoie MB, Paciorek A, Zhang L, Van Blarigan EL, Sommovilla N, Abrams D, Atreya CE, Bergsland EK, Chern H, Kelley RK, Ko A, Laffan A, Sarin A, Varma MG, Venook AP, Van Loon K| | PubMed
  88. Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial.
    Abou-Alfa GK, Shi Q, Knox JJ, Kaubisch A, Niedzwiecki D, Posey J, Tan BR, Kavan P, Goel R, Lammers PE, Bekaii-Saab TS, Tam VC, Rajdev L, Kelley RK, El Dika I, Zemla T, Potaracke RI, Balletti J, El-Khoueiry AB, Harding JJ, Suga JM, Schwartz LH, Goldberg RM, Bertagnolli MM, Meyerhardt J, O'Reilly EM, Venook AP| | PubMed
  89. Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance).
    Brown JC, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, O'Neil BH, Shaw JE, Polite BN, Denlinger CS, Atkins JN, Goldberg RM, Ng K, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA| | PubMed
  90. Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance).
    Yuan C, Sato K, Hollis BW, Zhang S, Niedzwiecki D, Ou FS, Chang IW, O'Neil BH, Innocenti F, Lenz HJ, Blanke CD, Goldberg RM, Venook AP, Mayer RJ, Fuchs CS, Meyerhardt JA, Ng K| | PubMed
  91. Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology.
    Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming DA, Garrido-Laguna I, Grem JL, Hoffe SE, Hubbard J, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen KS, Saltz LB, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Johnson-Chilla A, Gregory KM, Gurski LA| | PubMed
  92. Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes.
    Lowery MA, Goff LW, Keenan BP, Jordan E, Wang R, Bocobo AG, Chou JF, O'Reilly EM, Harding JJ, Kemeny N, Capanu M, Griffin AC, McGuire J, Venook AP, Abou-Alfa GK, Kelley RK| | PubMed
  93. Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer.
    Piawah S, Venook AP| | PubMed
  94. Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405.
    Guercio BJ, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Sato K, Ng K, Van Blarigan E, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA| | PubMed
  95. Vitamin D Levels in Patients with Colorectal Cancer and Matched Household Members.
    Savoie MB, Paciorek A, Zhang L, Sommovilla N, Venook AP, Van Blarigan EL, Van Loon K| | PubMed
  96. High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma.
    Donner DB, Nakakura EK, Venook AP, Lenz HJ, Zhang W, Hwang J, Bergsland EK, Lin MH, Toriguchi K, Antonia RJ, Warren RS| | PubMed
  97. Reply to S. Sorscher.
    Innocenti F, Ou FS, Qu X, Zemla T, Niedzwiecki D, Tam R, Mahajan S, Goldberg RM, Bertagnolli MM, Blanke CD, Sanoff H, Atkins J, Polite B, Venook AP, Lenz HJ, Kabbarah O| | PubMed
  98. RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer.
    Gbenedio OM, Bonnans C, Grun D, Wang CY, Hatch AJ, Mahoney MR, Barras D, Matli M, Miao Y, Garcia KC, Tejpar S, Delorenzi M, Venook AP, Nixon AB, Warren RS, Roose JP, Depeille P| | PubMed
  99. Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).
    Lenz HJ, Ou FS, Venook AP, Hochster HS, Niedzwiecki D, Goldberg RM, Mayer RJ, Bertagnolli MM, Blanke CD, Zemla T, Qu X, Wirapati P, Tejpar S, Innocenti F, Kabbarah O| | PubMed
  100. Guidelines Insights: Hepatobiliary Cancers, Version 2.2019.
    Benson AB, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Anaya DA, Anders R, Are C, Brown D, Chang DT, Cloyd J, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Hammond LJ, Darlow SD| | PubMed
  101. Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome.
    Innocenti F, Ou FS, Qu X, Zemla TJ, Niedzwiecki D, Tam R, Mahajan S, Goldberg RM, Bertagnolli MM, Blanke CD, Sanoff H, Atkins J, Polite B, Venook AP, Lenz HJ, Kabbarah O| | PubMed
  102. Self-monitoring and reminder text messages to increase physical activity in colorectal cancer survivors (Smart Pace): a pilot randomized controlled trial.
    Van Blarigan EL, Chan H, Van Loon K, Kenfield SA, Chan JM, Mitchell E, Zhang L, Paciorek A, Joseph G, Laffan A, Atreya CE, Fukuoka Y, Miaskowski C, Meyerhardt JA, Venook AP| | PubMed
  103. Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance).
    Morales-Oyarvide V, Yuan C, Babic A, Zhang S, Niedzwiecki D, Brand-Miller JC, Sampson-Kent L, Ye X, Li Y, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Wu K, Willett WC, Giovannucci EL, Wolpin BM, Meyerhardt JA, Fuchs CS, Ng K| | PubMed
  104. Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance).
    Schrag D, Weiser M, Saltz L, Mamon H, Gollub M, Basch E, Venook A, Shi Q| | PubMed
  105. Genetic variation determines VEGF-A plasma levels in cancer patients.
    Innocenti F, Jiang C, Sibley AB, Etheridge AS, Hatch AJ, Denning S, Niedzwiecki D, Shterev ID, Lin J, Furukawa Y, Kubo M, Kindler HL, Auman JT, Venook AP, Hurwitz HI, McLeod HL, Ratain MJ, Gordan R, Nixon AB, Owzar K| | PubMed
  106. Of Microbes and Microsatellites.
    Atreya CE, Venook AP| | PubMed
  107. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.
    Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK| | PubMed
  108. The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.
    Innocenti F, Owzar K, Jiang C, Etheridge AS, Gordân R, Sibley AB, Mulkey F, Niedzwiecki D, Glubb D, Neel N, Talamonti MS, Bentrem DJ, Seiser E, Yeh JJ, Van Loon K, McLeod H, Ratain MJ, Kindler HL, Venook AP, Nakamura Y, Kubo M, Petersen GM, Bamlet WR, McWilliams RR| | PubMed
  109. Being Present: A single-arm feasibility study of audio-based mindfulness meditation for colorectal cancer patients and caregivers.
    Atreya CE, Kubo A, Borno HT, Rosenthal B, Campanella M, Rettger JP, Joseph G, Allen IE, Venook AP, Altschuler A, Dhruva A| | PubMed
  110. Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance).
    Van Blarigan EL, Ou FS, Niedzwiecki D, Zhang S, Fuchs CS, Saltz L, Mayer RJ, Venook A, Ogino S, Song M, Benson A, Hantel A, Atkins JN, Giovannucci EL, Meyerhardt JA| | PubMed
  111. Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance).
    Guercio BJ, Zhang S, Niedzwiecki D, Li Y, Babic A, Morales-Oyarvide V, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Zoltick ES, Stampfer M, Ng K, Wu K, Willett WC, Giovannucci EL, Meyerhardt JA, Fuchs CS| | PubMed
  112. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
    Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Klümpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK| | PubMed
  113. Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
    Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass DA| | PubMed
  114. Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
    Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Gurski L, Freedman-Cass DA| | PubMed
  115. Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).
    Li M, Mulkey F, Jiang C, O'Neil BH, Schneider BP, Shen F, Friedman PN, Momozawa Y, Kubo M, Niedzwiecki D, Hochster HS, Lenz HJ, Atkins JN, Rugo HS, Halabi S, Kelly WK, McLeod HL, Innocenti F, Ratain MJ, Venook AP, Owzar K, Kroetz DL| | PubMed
  116. Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis: The CALGB 89803/Alliance Trial.
    Van Blarigan EL, Fuchs CS, Niedzwiecki D, Zhang S, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Giovannucci EL, Ng K, Meyerhardt JA| | PubMed
  117. Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance).
    Brown JC, Zhang S, Niedzwiecki D, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Li Y, Zhang X, Ng K, Willett WC, Giovannucci EL, Fuchs CS, Meyerhardt JA| | PubMed
  118. Association Between Intensity of Posttreatment Surveillance Testing and Detection of Recurrence in Patients With Colorectal Cancer.
    Snyder RA, Hu CY, Cuddy A, Francescatti AB, Schumacher JR, Van Loon K, You YN, Kozower BD, Greenberg CC, Schrag D, Venook A, McKellar D, Winchester DP, Chang GJ, Alliance for Clinical Trials in Oncology Network Cancer Surveillance Optimization Working Group| | PubMed
  119. Optimizing Adjuvant Therapy for Localized Colon Cancer and Treatment Selection in Advanced Colorectal Cancer.
    Grothey A, Venook AP| | PubMed
  120. Advances in Adjuvant Therapy for Colon Cancer: P value or Practical Value.
    Venook AP| | PubMed
  121. NCCN Guidelines Insights: Colon Cancer, Version 2.2018.
    Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Garrido-Laguna I, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass DA| | PubMed
  122. Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance).
    Fadelu T, Zhang S, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson AB, Atienza DM, Messino M, Kindler HL, Venook A, Ogino S, Ng K, Wu K, Willett W, Giovannucci E, Meyerhardt J, Bao Y, Fuchs CS| | PubMed
  123. Marine ω-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance).
    Van Blarigan EL, Fuchs CS, Niedzwiecki D, Ye X, Zhang S, Song M, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Giovannucci EL, Meyerhardt JA| | PubMed
  124. The Developing Role of Anti-Epidermal Growth Factor Receptor Agents in the Treatment of Advanced or Metastatic Colorectal Cancer.
    Ursem C, Venook AP| | PubMed
  125. Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).
    Fuchs CS, Niedzwiecki D, Mamon HJ, Tepper JE, Ye X, Swanson RS, Enzinger PC, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG, Gunderson LL, Goldberg RM, Venook AP, Ilson D, O'Reilly E, Ciombor K, Berg DJ, Meyerhardt J, Mayer RJ| | PubMed
  126. Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance).
    McCleary NJ, Hubbard J, Mahoney MR, Meyerhardt JA, Sargent D, Venook A, Grothey A| | PubMed
  127. Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.
    Basch E, Dueck AC, Rogak LJ, Minasian LM, Kelly WK, O'Mara AM, Denicoff AM, Seisler D, Atherton PJ, Paskett E, Carey L, Dickler M, Heist RS, Himelstein A, Rugo HS, Sikov WM, Socinski MA, Venook AP, Weckstein DJ, Lake DE, Biggs DD, Freedman RA, Kuzma C, Kirshner JJ, Schrag D| | PubMed
  128. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
    Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, Heinemann V, Van Cutsem E, Pignon JP, Tabernero J, Cervantes A, Ciardiello F| | PubMed
  129. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB, Mulkerin DL, Mayer RJ, Blanke C| | PubMed
  130. Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance).
    Fuchs MA, Yuan C, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Innocenti F, Warren RS, Bertagnolli MM, Ogino S, Giovannucci EL, Horvath E, Meyerhardt JA, Ng K| | PubMed
  131. NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017.
    Benson AB, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Schmidt C, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Zhu AX, Hoffmann KG, Darlow S| | PubMed
  132. Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.
    Benson AB, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, Deming D, Engstrom PF, Enzinger PC, Fichera A, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wu CS, Gregory KM, Freedman-Cass D| | PubMed
  133. Differences in symptom occurrence, severity, and distress ratings between patients with gastrointestinal cancers who received chemotherapy alone or chemotherapy with targeted therapy.
    Tantoy IY, Dhruva A, Cataldo J, Venook A, Cooper BA, Paul SM, Levine JD, Conley YP, Cartwright F, Lee K, Wright F, Miaskowski C| | PubMed
  134. Reply to L. Casadaban et al.
    Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F| | PubMed
  135. Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer.
    Parikh A, Atreya C, Korn WM, Venook AP| | PubMed
  136. Right-sided vs left-sided colorectal cancer.
    Venook AP| | PubMed
  137. Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference.
    Abou-Alfa GK, Andersen JB, Chapman W, Choti M, Forbes SJ, Gores GJ, Hong TS, Harding JJ, Vander Heiden MG, Javle M, Kelley RK, Kwong LN, Lowery M, Merrell A, Miyabe K, Rhim A, Saha S, Sia D, Tanasanvimon S, Venook A, Valle JW, Walesky C, Whetstine J, Willenbring H, Zhu AX, Mayer D, Stanger BZ| | PubMed
  138. Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location.
    Atreya CE, Greene C, McWhirter RM, Ikram NS, Allen IE, Van Loon K, Venook AP, Yeh BM, Behr SC| | PubMed
  139. Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study.
    Fidelman N, Kerlan RK, Hawkins RA, Pampaloni M, Taylor AG, Kohi MP, Kolli KP, Atreya CE, Bergsland EK, Kelley RK, Ko AH, Korn WM, Van Loon K, McWhirter RM, Luan J, Johanson C, Venook AP| | PubMed
  140. Role of Biologics in Colon Cancer: Still Not Clear.
    Atreya CE, Venook AP| | PubMed
  141. Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials.
    Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK| | PubMed
  142. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.
    Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh Rde W, Collisson E, Schwartz L, Frankel W, Martin R, Conway W, Truty M, Kindler H, Lowy AM, Bekaii-Saab T, Philip P, Talamonti M, Cardin D, LoConte N, Shen P, Hoffman JP, Venook AP| | PubMed
  143. Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
    Hatch AJ, Sibley AB, Starr MD, Brady JC, Jiang C, Jia J, Bowers DL, Pang H, Owzar K, Niedzwiecki D, Innocenti F, Venook AP, Hurwitz HI, Nixon AB, Alliance for Clinical Trials in Oncology| | PubMed
  144. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study.
    Marrero JA, Kudo M, Venook AP, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JH, de Guevara LL, Papandreou C, Takayama T, Sanyal AJ, Yoon SK, Nakajima K, Lehr R, Heldner S, Lencioni R| | PubMed
  145. Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance).
    Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F| | PubMed
  146. CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
    Enzinger PC, Burtness BA, Niedzwiecki D, Ye X, Douglas K, Ilson DH, Villaflor VM, Cohen SJ, Mayer RJ, Venook A, Benson AB, Goldberg RM| | PubMed
  147. Adjuvant Therapy Trials.
    Ursem C, Van Loon K, Venook A| | PubMed
  148. Metastatic Colorectal Cancer: Lessons Learned, Future Possibilities.
    Venook AP| | PubMed
  149. A phase II study of axitinib in advanced neuroendocrine tumors.
    Strosberg JR, Cives M, Hwang J, Weber T, Nickerson M, Atreya CE, Venook A, Kelley RK, Valone T, Morse B, Coppola D, Bergsland EK| | PubMed
  150. Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study.
    Kudo M, Lencioni R, Marrero JA, Venook AP, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Ladrón de Guevara L, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Ye SL| | PubMed
  151. Gene Expression Profiling of Evening Fatigue in Women Undergoing Chemotherapy for Breast Cancer.
    Kober KM, Dunn L, Mastick J, Cooper B, Langford D, Melisko M, Venook A, Chen LM, Wright F, Hammer M, Schmidt BL, Levine J, Miaskowski C, Aouizerat BE| | PubMed
  152. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma.
    Ko AH, LoConte N, Tempero MA, Walker EJ, Kate Kelley R, Lewis S, Chang WC, Kantoff E, Vannier MW, Catenacci DV, Venook AP, Kindler HL| | PubMed
  153. TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON.
    Geschwind JF, Kudo M, Marrero JA, Venook AP, Chen XP, Bronowicki JP, Dagher L, Furuse J, Ladrón de Guevara L, Papandreou C, Sanyal AJ, Takayama T, Ye SL, Yoon SK, Nakajima K, Lehr R, Heldner S, Lencioni R| | PubMed
  154. NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys.
    Kurzrock R, Colevas AD, Olszanski A, Akerley W, Arteaga CL, Carson WE, Clark JW, DiPersio JF, Ettinger DS, Morgan RJ, Schwartzberg LS, Venook AP, Gocke CD, Tait J, Stewart FM| | PubMed
  155. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.
    Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S| | PubMed
  156. Subgroups of chemotherapy patients with distinct morning and evening fatigue trajectories.
    Kober KM, Cooper BA, Paul SM, Dunn LB, Levine JD, Wright F, Hammer MJ, Mastick J, Venook A, Aouizerat BE, Miaskowski C| | PubMed
  157. The value and effectiveness of angiogenesis inhibitors for colorectal cancer.
    Venook AP| | PubMed
  158. Trying to Understand Differing Results of FIRE-3 and 80405: Does the First Treatment Matter More Than Others?
    O'Neil BH, Venook AP| | PubMed
  159. Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance).
    Guercio BJ, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Hu FB, Ogino S, Wu K, Willett WC, Giovannucci EL, Meyerhardt JA, Fuchs CS| | PubMed
  160. A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma.
    Ko AH, Bekaii-Saab T, Van Ziffle J, Mirzoeva OM, Joseph NM, Talasaz A, Kuhn P, Tempero MA, Collisson EA, Kelley RK, Venook AP, Dito E, Ong A, Ziyeh S, Courtin R, Linetskaya R, Tahiri S, Korn WM| | PubMed
  161. On the Verge: Immunotherapy for Colorectal Carcinoma.
    Oh DY, Venook AP, Fong L| | PubMed
  162. Rectal Cancer, Version 2.2015.
    Benson AB, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Grothey A, Hochster HS, Hunt S, Kamel A, Kirilcuk N, Leong LA, Lin E, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass D| | PubMed
  163. Special Series: Advances in GI Cancer.
    Meyerhardt JA, Tepper JE, Venook AP| | PubMed
  164. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls.
    Kelley RK, Magbanua MJ, Butler TM, Collisson EA, Hwang J, Sidiropoulos N, Evason K, McWhirter RM, Hameed B, Wayne EM, Yao FY, Venook AP, Park JW| | PubMed
  165. Phase I trial of sorafenib following liver transplantation in patients with high-risk hepatocellular carcinoma.
    Siegel AB, El-Khoueiry AB, Finn RS, Guthrie KA, Goyal A, Venook AP, Blanke CD, Verna EC, Dove L, Emond J, Kato T, Samstein B, Busuttil R, Remotti H, Coffey A, Brown RS| | PubMed
  166. Bevacizumab vs EGFR antibodies in metastatic colorectal cancer.
    Venook AP| | PubMed
  167. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.
    Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, Dizon DS, Fine HA, Kalemkerian GP, Moasser M, Neuss MN, O'Day SJ, Odenike O, Ryan CJ, Schilsky RL, Schwartz GK, Venook AP, Wong SL, Patel JD| | PubMed
  168. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.
    Daud AI, Ashworth MT, Strosberg J, Goldman JW, Mendelson D, Springett G, Venook AP, Loechner S, Rosen LS, Shanahan F, Parry D, Shumway S, Grabowsky JA, Freshwater T, Sorge C, Kang SP, Isaacs R, Munster PN| | PubMed
  169. Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
    Cushman SM, Jiang C, Hatch AJ, Shterev I, Sibley AB, Niedzwiecki D, Venook AP, Owzar K, Hurwitz HI, Nixon AB| | PubMed
  170. A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma.
    Cinar P, Calkins SM, Venook AP, Kelley RK| | PubMed
  171. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.
    Ng K, Meyerhardt JA, Chan AT, Sato K, Chan JA, Niedzwiecki D, Saltz LB, Mayer RJ, Benson AB, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Venook AP, Ogino S, Giovannucci EL, Fuchs CS| | PubMed
  172. Bone metastases and skeletal-related events from neuroendocrine tumors.
    Van Loon K, Zhang L, Keiser J, Carrasco C, Glass K, Ramirez MT, Bobiak S, Nakakura EK, Venook AP, Shah MH, Bergsland EK| | PubMed
  173. Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802).
    Lamont EB, Schilsky RL, He Y, Muss H, Cohen HJ, Hurria A, Meilleur A, Kindler HL, Venook A, Lilenbaum R, Niell H, Goldberg RM, Joffe S, Alliance for Clinical Trials in Oncology| | PubMed
  174. Progression-free survival: helpful biomarker or clinically meaningless end point?
    Venook AP, Tabernero J| | PubMed
  175. NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.
    Venook AP, Arcila ME, Benson AB, Berry DA, Camidge DR, Carlson RW, Choueiri TK, Guild V, Kalemkerian GP, Kurzrock R, Lovly CM, McKee AE, Morgan RJ, Olszanski AJ, Redman MW, Stearns V, McClure J, Birkeland ML| | PubMed
  176. Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.
    Song EK, Tai WM, Messersmith WA, Bagby S, Purkey A, Quackenbush KS, Pitts TM, Wang G, Blatchford P, Yahn R, Kaplan J, Tan AC, Atreya CE, Eckhardt G, Kelley RK, Venook A, Kwak EL, Ryan D, Arcaroli JJ| | PubMed
  177. 25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance).
    Van Loon K, Owzar K, Jiang C, Kindler HL, Mulcahy MF, Niedzwiecki D, O'Reilly EM, Fuchs C, Innocenti F, Venook AP, Alliance for Clinical Trials in Oncology| | PubMed
  178. Hepatobiliary cancers, version 2.2014.
    Benson AB, D'Angelica MI, Abrams TA, Are C, Bloomston PM, Chang DT, Clary BM, Covey AM, Ensminger WD, Iyer R, Kelley RK, Linehan D, Malafa MP, Meranze SG, Park JO, Pawlik T, Posey JA, Scaife C, Schefter T, Sigurdson ER, Tian GG, Vauthey JN, Venook AP, Yen Y, Zhu AX, Hoffmann KG, McMillian NR, Sundar H| | PubMed
  179. Colon cancer, version 3.2014.
    Benson AB, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, Messersmith W, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass DA, National Comprehensive Cancer Network| | PubMed
  180. Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance).
    Fuchs MA, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Wu K, Willett WC, Giovannucci EL, Meyerhardt JA| | PubMed
  181. 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study.
    Fidelman N, Kerlan RK, Hawkins RA, Taylor AG, Kohi MP, Kolli KP, Bergsland EK, Kelley RK, Ko AH, Korn WM, McWhirter RM, Luan J, Venook AP| | PubMed
  182. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.
    Shiovitz S, Bertagnolli MM, Renfro LA, Nam E, Foster NR, Dzieciatkowski S, Luo Y, Lao VV, Monnat RJ, Emond MJ, Maizels N, Niedzwiecki D, Goldberg RM, Saltz LB, Venook A, Warren RS, Grady WM, Alliance for Clinical Trials in Oncology| | PubMed
  183. International adaptations of NCCN Clinical Practice Guidelines in Oncology.
    Carlson RW, Larsen JK, McClure J, Fitzgerald CL, Venook AP, Benson AB, Anderson BO| | PubMed
  184. Progress against GI cancer during the American Society of Clinical Oncology's first 50 years.
    Mayer RJ, Venook AP, Schilsky RL| | PubMed
  185. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.
    Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, Garrett-Mayer E, Herbst RS, Lilenbaum RC, Sima C, Venook AP, Gonen M, Schilsky RL, Meropol NJ, Schnipper LE| | PubMed
  186. Curable patient with metastatic colorectal cancer: balancing effective therapies and toxicities.
    Van Loon K, Venook AP| | PubMed
  187. Colorectal cancer: all hands on deck.
    Venook AP, Weiser MR, Tepper JE| | PubMed
  188. A review of hepatocellular carcinoma (HCC) staging systems.
    Subramaniam S, Kelley RK, Venook AP| | PubMed
  189. Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).
    Nixon AB, Pang H, Starr MD, Friedman PN, Bertagnolli MM, Kindler HL, Goldberg RM, Venook AP, Hurwitz HI, Alliance for Clinical Trials In Oncology| | PubMed
  190. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer.
    Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK| | PubMed
  191. Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance.
    Jeon J, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Wigler DS, Atienza D, Messino M, Kindler H, Venook A, Fuchs CS, Meyerhardt JA| | PubMed
  192. Biomarkers in colon cancer: the chasm between expectations and reality.
    Van Loon K, Venook AP| | PubMed
  193. The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached?
    Abou-Alfa GK, Venook AP| | PubMed
  194. Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines.
    Benson AB, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett CG, Gregory KM, Freedman-Cass DA, National Comprehensive Cancer Network| | PubMed
  195. Predictive biomarkers for bevacizumab: are we there yet?
    Maru D, Venook AP, Ellis LM| | PubMed
  196. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.
    Venook AP, Niedzwiecki D, Lopatin M, Ye X, Lee M, Friedman PN, Frankel W, Clark-Langone K, Millward C, Shak S, Goldberg RM, Mahmoud NN, Warren RS, Schilsky RL, Bertagnolli MM| | PubMed
  197. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
    Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P, Luttgen MS, Grabowsky JA, Stucky-Marshall L, Korn WM, Ko AH, Bergsland EK, Benson AB, Venook AP| | PubMed
  198. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design.
    Katz MH, Marsh R, Herman JM, Shi Q, Collison E, Venook AP, Kindler HL, Alberts SR, Philip P, Lowy AM, Pisters PW, Posner MC, Berlin JD, Ahmad SA| | PubMed
  199. Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines.
    Benson AB, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett CG, Gregory KM, Freedman-Cass DA| | PubMed
  200. Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405.
    Van Loon K, Wigler D, Niedzwiecki D, Venook AP, Fuchs C, Blanke C, Saltz L, Goldberg RM, Meyerhardt JA| | PubMed
  201. Biologic agents in the treatment of colorectal cancer: the last decade; the lost decade?
    Venook AP, Saltz LB| | PubMed
  202. Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium.
    Ang CS, Kelley RK, Choti MA, Cosgrove DP, Chou JF, Klimstra D, Torbenson MS, Ferrell L, Pawlik TM, Fong Y, O'Reilly EM, Ma J, McGuire J, Vallarapu GP, Griffin A, Stipa F, Capanu M, Dematteo RP, Venook AP, Abou-Alfa GK| | PubMed
  203. Novel therapeutics in hepatocellular carcinoma: how can we make progress?
    Kelley RK, Venook AP| | PubMed
  204. Rectal cancer.
    Benson AB, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fuchs CS, Grem JL, Hunt S, Leong LA, Lin E, Martin MG, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett CG, Freedman-Cass DA, Gregory KM| | PubMed
  205. Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.
    Meyerhardt JA, Sato K, Niedzwiecki D, Ye C, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Wigler DS, Venook A, Fuchs CS| | PubMed
  206. Counterpoint: Adjuvant therapy in stage II colon cancer: pain not justified by the gain.
    Van Loon K, Venook AP| | PubMed
  207. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
    Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA| | PubMed
  208. When progressive disease does not mean treatment failure: reconsidering the criteria for progression.
    Oxnard GR, Morris MJ, Hodi FS, Baker LH, Kris MG, Venook AP, Schwartz LH| | PubMed
  209. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients.
    Parekh JR, Wang SC, Bergsland EK, Venook AP, Warren RS, Kim GE, Nakakura EK| | PubMed
  210. Can we cure cholangiocarcinoma with neoadjuvant chemoradiation and liver transplantation? Time for a multicenter trial.
    Kelley RK, Hirose R, Venook AP| | PubMed
  211. Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines.
    Benson AB, Arnoletti JP, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Engstrom PF, Enzinger PC, Fakih MG, Fleshman JW, Fuchs CS, Grem JL, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett C, Freedman-Cass DA, National Comprehensive Cancer Network| | PubMed
  212. Metastatic colorectal cancer: a curable disease.
    Van Loon K, Venook AP| | PubMed
  213. Predictive biomarkers in advance of a companion drug: ahead of their time?
    Kelley RK, Atreya C, Venook AP, Febbo PG| | PubMed
  214. Development of a research agenda for the management of metastatic colorectal cancer: proceedings from a multidisciplinary research consensus panel.
    Janne d'Othée B, Sofocleous CT, Hanna N, Lewandowski RJ, Soulen MC, Vauthey JN, Cohen SJ, Venook AP, Johnson MS, Kennedy AS, Murthy R, Geschwind JF, Kee ST| | PubMed
  215. Is there currently an established role for the use of predictive or prognostic molecular markers in the management of colorectal cancer? A point/counterpoint.
    Venook AP, Bendell JC, Warren RS| | PubMed
  216. Biomarker use in colorectal cancer therapy.
    Kelley RK, Wang G, Venook AP| | PubMed
  217. Colon cancer.
    Benson AB, Arnoletti JP, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Engstrom PF, Enzinger PC, Fleshman JW, Fuchs CS, Grem JL, Knol JA, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett C, National Comprehensive Cancer Network| | PubMed
  218. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803.
    Ng K, Ogino S, Meyerhardt JA, Chan JA, Chan AT, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Benson AB, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Bertagnolli MM, Venook AP, Fuchs CS| | PubMed
  219. Adjuvant treatment of colon cancer: what is next?
    Van Loon K, Venook AP| | PubMed
  220. Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303).
    Roberts AS, Campa MJ, Gottlin EB, Jiang C, Owzar K, Kindler HL, Venook AP, Goldberg RM, O'Reilly EM, Patz EF| | PubMed
  221. Lactic acidosis and colon cancer: oncologic emergency?
    Espinoza AM, Venook AP| | PubMed
  222. Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?
    Kelley RK, Venook AP| | PubMed
  223. Long-term outcome of early-stage rectal cancer undergoing standard resection and local excision.
    Peng J, Chen W, Venook AP, Sheng W, Xu Y, Guan Z, Cai G, Cai S| | PubMed
  224. "And what other medications are you taking?".
    Gordan JD, Chay WY, Kelley RK, Ko AH, Choo SP, Venook AP| | PubMed
  225. Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer.
    Kelley RK, Van Bebber SL, Phillips KA, Venook AP| | PubMed
  226. Perineural invasion in pT3N0 rectal cancer: the incidence and its prognostic effect.
    Peng J, Sheng W, Huang D, Venook AP, Xu Y, Guan Z, Cai S| | PubMed
  227. Nonadherence to imatinib during an economic downturn.
    Kelley RK, Venook AP| | PubMed
  228. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting.
    Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, Poon R, Schwartz L, Tepper J, Yao F, Haller D, Mooney M, Venook A| | PubMed
  229. Hepatocellular carcinoma: Ablate and wait versus rapid transplantation.
    Roberts JP, Venook A, Kerlan R, Yao F| | PubMed
  230. Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study.
    Lencioni R, Marrero J, Venook A, Ye SL, Kudo M| | PubMed
  231. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement.
    Schwarz RE, Abou-Alfa GK, Geschwind JF, Krishnan S, Salem R, Venook AP, American Hepato-Pancreato-Biliary Association, Society of Surgical Oncology, Society for Surgery of the Alimentary Tract| | PubMed
  232. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.
    Chung KY, Gore I, Fong L, Venook A, Beck SB, Dorazio P, Criscitiello PJ, Healey DI, Huang B, Gomez-Navarro J, Saltz LB| | PubMed
  233. Identification of unknown primary tumors in patients with neuroendocrine liver metastases.
    Wang SC, Parekh JR, Zuraek MB, Venook AP, Bergsland EK, Warren RS, Nakakura EK| | PubMed
  234. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
    Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA| | PubMed
  235. NCCN clinical practice guidelines in oncology. Anal carcinoma.
    Engstrom PF, Arnoletti JP, Benson AB, Berlin JD, Berry JM, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Knol JA, Leong LA, Lin E, Mulcahy MF, Rohren E, Ryan DP, Saltz L, Shibata D, Skibber JM, Small W, Sofocleous C, Thomas J, Venook AP, Willett C, NCCN| | PubMed
  236. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective.
    Venook AP, Papandreou C, Furuse J, de Guevara LL| | PubMed
  237. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?
    Lencioni R, Chen XP, Dagher L, Venook AP| | PubMed
  238. NCCN Clinical Practice Guidelines in Oncology: colon cancer.
    Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C, National Comprehensive Cancer Network| | PubMed
  239. NCCN Clinical Practice Guidelines in Oncology: rectal cancer.
    Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C, National Comprehensive Cancer Network| | PubMed
  240. Drug development in advanced colorectal cancer: challenges and opportunities.
    Kelley R, Venook AP| | PubMed
  241. NCCN clinical practice guidelines in oncology: hepatobiliary cancers.
    Benson AB, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, Covey A, Curley SA, D'Angelica MI, Davila R, Ensminger WD, Gibbs JF, Laheru D, Malafa MP, Marrero J, Meranze SG, Mulvihill SJ, Park JO, Posey JA, Sachdev J, Salem R, Sigurdson ER, Sofocleous C, Vauthey JN, Venook AP, Goff LW, Yen Y, Zhu AX| | PubMed
  242. A Phase II Study of Long-Acting Octreotide in Patients With Advanced Hepatocellular Carcinoma and CLIP Score of 3 or Higher.
    Shah U, O'Neil B, Allen J, Goldberg RM, Bernard S, Moore D, Venook AP, Morse MM| | PubMed
  243. Design issues in dose-finding Phase I trials for combinations of two agents.
    Fan SK, Venook AP, Lu Y| | PubMed
  244. Sorafenib in hepatocellular carcinoma: separating the hype from the hope.
    Kelley RK, Venook AP| | PubMed
  245. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy.
    Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA| | PubMed
  246. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma.
    Sterling RK, Jeffers L, Gordon F, Venook AP, Reddy KR, Satomura S, Kanke F, Schwartz ME, Sherman M| | PubMed
  247. NCCN Task Force Report: mTOR inhibition in solid tumors.
    Figlin RA, Brown E, Armstrong AJ, Akerley W, Benson AB, Burstein HJ, Ettinger DS, Febbo PG, Fury MG, Hudes GR, Kies MS, Kwak EL, Morgan RJ, Mortimer J, Reckamp K, Venook AP, Worden F, Yen Y| | PubMed
  248. The impact of new data in the treatment of advanced hepatocellular carcinoma.
    Abou-Alfa GK, Venook AP| | PubMed
  249. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
    Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA| | PubMed
  250. Responding to the rising incidence of hepatocellular carcinoma with targeted therapy.
    Choo SP, Venook AP| | PubMed
  251. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
    Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA| | PubMed
  252. Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma.
    Berlin JD, Venook A, Bergsland E, Rothenberg M, Lockhart AC, Rosen L| | PubMed
  253. Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy.
    O'Neil BH, Venook AP| | PubMed
  254. A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903.
    Posner MC, Niedzwiecki D, Venook AP, Hollis DR, Kindler HL, Martin EW, Schilsky RL, Goldberg RM, Mayer RJ| | PubMed
  255. Section I: essentials of ensuring excellence in cancer care.
    Goldberg RM, Marshall JL, Kachnic LA, Venook AP| | PubMed
  256. Section III: Treatment of Advanced Gastrointestinal Cancers.
    Hochster HS, O'Reilly EM, Ajani JA, Venook AP| | PubMed
  257. Section IV: Significance of Recent Study Results and Future Research Directions in Gastrointestinal Oncology.
    Goldberg RM, Marshall JL, Ajani JA, Philip PA, O'Reilly EM, Venook AP| | PubMed
  258. Colon cancer.
    Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Early DS, Fakih MG, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW, Rao S, Saltz L, Shibata D, Skibber JM, Venook AP, Fox Chase Cancer Center Partners| | PubMed
  259. Rectal cancer.
    Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Early DS, Fakih MG, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW, Rao S, Saltz L, Shibata D, Skibber JM, Venook AP, National Comprehensive Cancer Network| | PubMed
  260. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.
    Kavanagh B, Ko A, Venook A, Margolin K, Zeh H, Lotze M, Schillinger B, Liu W, Lu Y, Mitsky P, Schilling M, Bercovici N, Loudovaris M, Guillermo R, Lee SM, Bender J, Mills B, Fong L| | PubMed
  261. An alternative therapy for patients with hepatic impairment?
    Choo SP, Venook AP| | PubMed
  262. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.
    Hecht JR, Patnaik A, Berlin J, Venook A, Malik I, Tchekmedyian S, Navale L, Amado RG, Meropol NJ| | PubMed
  263. End points in advanced colon cancer clinical trials: a review and proposal.
    Allegra C, Blanke C, Buyse M, Goldberg R, Grothey A, Meropol NJ, Saltz L, Venook A, Yothers G, Sargent D| | PubMed
  264. Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis.
    Sterling RK, Jeffers L, Gordon F, Sherman M, Venook AP, Reddy KR, Satomura S, Schwartz ME| | PubMed
  265. Systemic and regional nonsurgical therapy--what is the optimal strategy for metastatic neuroendocrine cancer?
    Nakakura EK, Venook AP, Bergsland EK| | PubMed
  266. Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma.
    Venook AP, Blanke CD, Niedzwiecki D, Lenz HJ, Taylor JR, Hollis DR, Sutherland S, Goldberg RM| | PubMed
  267. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.
    Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA| | PubMed
  268. Frequency of hepatic contour abnormalities and signs of portal hypertension at CT in patients receiving chemotherapy for breast cancer metastatic to the liver.
    Qayyum A, Lee GK, Yeh BM, Allen JN, Venook AP, Coakley FV| | PubMed
  269. Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement.
    Bartlett DL, Berlin J, Lauwers GY, Messersmith WA, Petrelli NJ, Venook AP| | PubMed
  270. Hepatobiliary cancers. Clinical practice guidelines in oncology.
    Benson AB, Bekaii-Saab T, Ben-Josef E, Blumgart L, Clary BM, Curley SA, Davila R, Earle CC, Ensminger WD, Gibbs JF, Laheru D, Langnas AN, Mulvihill SJ, Nemcek AA, Posey JA, Sigurdson ER, Sinanan M, Vauthey JN, Venook AP, Wagman LD, Yeatman TJ, National Comprehensive Cancer Network| | PubMed
  271. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.
    Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, Meyerhardt JA, Heymach JV, Fogler WE, Sidor C, Michelini A, Kinsella K, Venook AP, Fuchs CS| | PubMed
  272. The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective.
    Ratain MJ, Miller AA, McLeod HL, Venook AP, Egorin MJ, Schilsky RL| | PubMed
  273. Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial.
    Atencio IA, Grace M, Bordens R, Fritz M, Horowitz JA, Hutchins B, Indelicato S, Jacobs S, Kolz K, Maneval D, Musco ML, Shinoda J, Venook A, Wen S, Warren R| | PubMed
  274. Targeted therapy in colorectal cancer.
    Rajpal S, Venook AP| | PubMed
  275. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.
    Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA| | PubMed
  276. Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma.
    Venook AP, Blanke CD, Niedzwiecki D, Lenz HJ, Taylor JR, Hollis DR, Sutherland S, Goldberg RM| | PubMed
  277. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.
    Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA| | PubMed
  278. Anal canal cancer clinical practice guidelines in oncology.
    Engstrom PF, Benson AB, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW, Rao S, Saif MW, Saltz L, Skibber JM, Venook AP, Yeatman TJ, National Comprehensive Cancer Network| | PubMed
  279. Colon cancer clinical practice guidelines in oncology.
    Engstrom PF, Benson AB, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW, Rao S, Saif MW, Saltz L, Skibber JM, Venook AP, Yeatman TJ, National Comprehensive Cancer Network| | PubMed
  280. Rectal cancer clinical practice guidelines in oncology.
    Engstrom PF, Benson AB, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW, Rao S, Saif MW, Saltz L, Skibber JM, Venook AP, Yeatman TJ, National Comprehensive Cancer Network| | PubMed
  281. Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma.
    Venook AP| | PubMed
  282. Critical evaluation of current treatments in metastatic colorectal cancer.
    Venook A| | PubMed
  283. The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma.
    Yao FY, Kinkhabwala M, LaBerge JM, Bass NM, Brown R, Kerlan R, Venook A, Ascher NL, Emond JC, Roberts JP| | PubMed
  284. Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer.
    Mehta KR, Nakao K, Zuraek MB, Ruan DT, Bergsland EK, Venook AP, Moore DH, Tokuyasu TA, Jain AN, Warren RS, Terdiman JP, Waldman FM| | PubMed
  285. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials.
    Alberts DS, Muggia FM, Carmichael J, Winer EP, Jahanzeb M, Venook AP, Skubitz KM, Rivera E, Sparano JA, DiBella NJ, Stewart SJ, Kavanagh JJ, Gabizon AA| | PubMed
  286. Cetuximab in the treatment of colorectal cancer.
    Goldberg RM, Venook AP, Schilsky RL| | PubMed
  287. Regional therapy of liver metastases.
    Whisenant J, Venook A| | PubMed
  288. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
    Venook AP| | PubMed
  289. Key research issues in the management of hepatocellular carcinoma.
    Venook AP| | PubMed
  290. Defining the role of hepatic arterial infusion chemotherapy in metastatic colorectal cancer.
    Whisenant J, Venook A| | PubMed
  291. Hepatocellular carcinoma: epidemic and treatment.
    Allen J, Venook A| | PubMed
  292. Reactivation of hepatitis C virus after chemotherapy for colon cancer.
    Melisko ME, Fox R, Venook A| | PubMed
  293. Hepatocellular carcinoma: regional therapy with a magnetic targeted carrier bound to doxorubicin in a dual MR imaging/ conventional angiography suite--initial experience with four patients.
    Wilson MW, Kerlan RK, Fidelman NA, Venook AP, LaBerge JM, Koda J, Gordon RL| | PubMed
  294. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.
    Venook AP, Enders Klein C, Fleming G, Hollis D, Leichman CG, Hohl R, Byrd J, Budman D, Villalona M, Marshall J, Rosner GL, Ramirez J, Kastrissios H, Ratain MJ| | PubMed
  295. Colorectal metastases confined to the liver: a unique opportunity?
    Venook AP| | PubMed
  296. Induction therapy in patients with metastatic colorectal cancer.
    Venook AP| | PubMed
  297. Adjuvant and neoadjuvant therapy for esophageal cancer: a critical reappraisal.
    Visser BC, Venook AP, Patti MG| | PubMed
  298. Testing the water before diving off the cutting edge.
    Venook AP| | PubMed
  299. Shedding old paradigms: developing viruses to treat cancer.
    Bergsland EK, Venook AP| | PubMed
  300. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.
    Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP| | PubMed
  301. Therapeutic approaches to metastasis confined to the liver.
    Venook AP, Warren RS| | PubMed
  302. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial.
    Mulvihill S, Warren R, Venook A, Adler A, Randlev B, Heise C, Kirn D| | PubMed
  303. Hepatocellular carcinoma.
    Venook AP| | PubMed
  304. NCCN Practice Guidelines for Colorectal Cancer.
    Benson AB, Choti MA, Cohen AM, Doroshow JH, Fuchs C, Kiel K, Martin EW, McGinn C, Petrelli NJ, Posey JA, Skibber JM, Venook A, Yeatman TJ, National Comprehensive Cancer Network| | PubMed
  305. Hepatocellular carcinoma.
    Bergsland EK, Venook AP| | PubMed
  306. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.
    Venook AP, Egorin MJ, Rosner GL, Hollis D, Mani S, Hawkins M, Byrd J, Hohl R, Budman D, Meropol NJ, Ratain MJ| | PubMed
  307. Hepatic arterial infusion of chemotherapy for metastatic colorectal cancer.
    Venook AP, Althaus B, Warren RS| | PubMed
  308. Regional strategies for managing hepatocellular carcinoma.
    Venook AP| | PubMed
  309. Transcatheter embolization for the treatment of misperfusion after hepatic artery chemoinfusion pump implantation.
    Bloom AI, Gordon RL, Ahl KH, Kerlan RK, LaBerge JM, Wilson MW, Venook AP, Warren R| | PubMed
  310. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.
    Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, Saltz L, Dandona P, Anthony L| | PubMed
  311. Embolization and chemoembolization therapy for neuroendocrine tumors.
    Venook AP| | PubMed
  312. Tamoxifen in liver disease: potential exacerbation of hepatic dysfunction.
    Floren LC, Hebert MF, Venook AP, Jordan VC, Cisneros A, Somberg KA| | PubMed
  313. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.
    Venook AP, Egorin MJ, Rosner GL, Brown TD, Jahan TM, Batist G, Hohl R, Budman D, Ratain MJ, Kearns CM, Schilsky RL| | PubMed
  314. Update on hepatic intra-arterial chemotherapy.
    Venook AP| | PubMed
  315. Can a vitamin prevent hepatocellular carcinoma?
    Venook AP| | PubMed
  316. Intra-abdominal desmoplastic small round-cell tumor: expansion of the pathologic profile.
    Dorsey BV, Benjamin LE, Rauscher F, Klencke B, Venook AP, Warren RS, Weidner N| | PubMed
  317. Practice guidelines for colorectal cancer.
    Venook A, Goodnight J, Kumar S, Taylor C, Gilden R, Figlin RA| | PubMed
  318. Practice guidelines for esophageal cancer.
    Goodnight J, Venook A, Ames M, Taylor C, Gilden R, Figlin RA| | PubMed
  319. Practice guidelines for gastric cancer.
    Venook A, Goodnight J, Smith NG, Taylor C, Gilden R, Figlin RA| | PubMed
  320. Practice guidelines for pancreatic cancer.
    Goodnight J, Venook A, Fringer J, Taylor C, Gilden R, Figlin RA| | PubMed
  321. Regional chemotherapy approaches for primary and metastatic liver tumors.
    Venook AP, Warren RS| | PubMed
  322. Pulmonary aspergillosis masquerading as progressive post-transplant lymphoma.
    Kirn D, Venook A, Pena I| | PubMed
  323. Liver transplantation for hepatocellular carcinoma: results with preoperative chemoembolization.
    Venook AP, Ferrell LD, Roberts JP, Emond J, Frye JW, Ring E, Ascher NL, Lake JR| | PubMed
  324. Treatment of hepatocellular carcinoma: too many options?
    Venook AP| | PubMed
  325. Gallium-avid thymic hyperplasia in an adult after chemotherapy for Hodgkin disease.
    Small EJ, Venook AP, Damon LE| | PubMed
  326. Liver transplantation for hepatocellular carcinoma.
    Venook AP| | PubMed
  327. A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma.
    Wilkinson MJ, Frye JW, Small EJ, Venook AP, Carroll PR, Ernest ML, Stagg RJ| | PubMed
  328. The Sweet syndrome during therapy with granulocyte colony-stimulating factor.
    Park JW, Mehrotra B, Barnett BO, Baron AD, Venook AP| | PubMed
  329. Hepatic cancers and their response to chemoembolization therapy. Quantitative image-guided 31P magnetic resonance spectroscopy.
    Meyerhoff DJ, Karczmar GS, Valone F, Venook A, Matson GB, Weiner MW| | PubMed
  330. Hepatic intra-arterial methylene blue injection during endoscopy: a method of detecting gastroduodenal misperfusion in patients receiving hepatic intra-arterial chemotherapy via an implanted pump.
    Frye JW, Venook AP, Ostroff JW, Mulvihill SJ, Warren RS, Pellegrini CA, Ring EJ, Stagg RJ| | PubMed
  331. Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer.
    Stagg RJ, Venook AP, Chase JL, Lewis BJ, Warren RS, Roh M, Mulvihill SJ, Grobman BJ, Rayner AA, Hohn DC| | PubMed
  332. Chemoembolization for hepatocellular carcinoma.
    Venook AP, Stagg RJ, Lewis BJ, Chase JL, Ring EJ, Maroney TP, Hohn DC| | PubMed
  333. Activity of coumarin and cimetidine in metastatic renal cell carcinoma.
    Venook AP, Davenport Y, Tseng A| | PubMed
  334. Elevated plasma tamoxifen levels in a patient with liver obstruction.
    DeGregorio MW, Wiebe VJ, Venook AP, Holleran WM| | PubMed
  335. Regional chemotherapy for colorectal cancer metastatic to the liver.
    Venook AP, Stagg RJ, Lewis BJ| | PubMed
  336. Pentoxifylline and aplastic anemia.
    Mass RD, Venook AP, Linker CA, Zipkin RE| | PubMed
  337. Prophylactic heparin in APL.
    Venook AP, Shuman MA, Corash L| | PubMed
  338. Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group.
    Venook AP, Tseng A, Meyers FJ, Silverberg I, Boles R, Fu KK, Jacobs CD| | PubMed
  339. Initiation of warfarin therapy: comparison of physician dosing with computer-assisted dosing.
    White RH, Hong R, Venook AP, Daschbach MM, Murray W, Mungall DR, Coleman RW| | PubMed